The initiation of coverage by RBC Capital with an Outperform rating and a price target of $14 suggests a positive outlook on Fulcrum Therapeutics' stock. This could lead to increased investor interest and potentially drive the stock price up in the short term, as market participants often react positively to favorable analyst coverage.